BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1081933)

  • 1. Cytotoxic activity of lymphocytes from patients with Hodgkin's disease.
    Holm G; Björkholm M; Mellstedt H; Johansson B
    Clin Exp Immunol; 1975 Sep; 21(3):376-83. PubMed ID: 1081933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in Hodgkin's disease. II. Role of the lymphocyte defect.
    Björkholm M; Holm G; Mellstedt H; Johansson B; Killander D; Sunblad R; Söderberg G
    Scand J Haematol; 1978 Apr; 20(4):306-18. PubMed ID: 653310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
    Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
    J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease.
    Jezewska E; Björkholm M; Giscombe R; Holm G; Tullgren O
    Clin Exp Immunol; 1985 Jul; 61(1):96-102. PubMed ID: 4042422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes.
    Matchett KM; Huang AT; Kremer WB
    J Clin Invest; 1973 Aug; 52(8):1908-17. PubMed ID: 4541673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal natural killer cell activity in Hodgkin's disease patients in remission.
    Douer D; Shaked N; Ramot B
    Clin Exp Immunol; 1987 Sep; 69(3):660-7. PubMed ID: 3665188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effector cells in human peripheral blood mediating mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity.
    Nelson DL; Bundy BM; Pitchon HE; Blaese RM; Strober W
    J Immunol; 1976 Nov; 117(5 Pt 1):1472-81. PubMed ID: 1087314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes.
    Hillinger SM; Herzig GP
    J Clin Invest; 1978 Jun; 61(6):1620-7. PubMed ID: 149140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cytotoxicity of effector cells of the peripheral blood, lymph nodes and spleen in Hodgkin's disease].
    Blokhina NG; Bykovskaia SN; Kharabadze MV; Kupriianova TA; Agafonov VA
    Biull Eksp Biol Med; 1989 Nov; 108(11):600-3. PubMed ID: 2633827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of cell surface abnormalities of T lymphocytes in hodgkin's disease after in vitro incubation in fetal sera.
    Fuks Z; Strober S; King DP; Kaplan HS
    J Immunol; 1976 Oct; 117(4):1331-5. PubMed ID: 1086325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer (NK) activity in patients with Hodgkin's disease before, during and after multiple-agent therapy.
    Frydecka I; Kotlarek-Haus S; Kuliszkiewicz-Janus M; Kuliczkowski K
    Arch Immunol Ther Exp (Warsz); 1990; 38(5-6):407-14. PubMed ID: 2130805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferritin-bearing lymphocytes in Hodgkin's disease.
    Koprivová H; Hermanská Z; Novák F; Blehová Z; Dienstbier Z
    Neoplasma; 1986; 33(1):63-9. PubMed ID: 3515213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative study of T and B lymphocytes in Hodgkin's disease.
    Bensa JC; Micouin C; Schaerer R; Sotto JJ; Hollard D
    Biomedicine; 1977 Apr; 26(2):137-44. PubMed ID: 326312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous mixed lymphocyte reaction in patients with Hodgkin's disease. Evidence for a T cell defect.
    Engleman EG; Benike CJ; Hoppe RT; Kaplan HS; Berberich FR
    J Clin Invest; 1980 Jul; 66(1):149-58. PubMed ID: 6447164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological study of patients with Hodgkin's disease in long-lasting not-maintained complete remission.
    Gobbi M; Fiacchini M; Tomasini I; Ruggero D; Lauria F; Tura S
    Boll Ist Sieroter Milan; 1977 Mar; 56(2):144-51. PubMed ID: 326273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of IgG lymphocytotoxins in untreated Hodgkin's disease (HD) patients.
    Jones DB; Elliott EV; Payne SV; Wright DH
    Clin Exp Immunol; 1978 Oct; 34(1):100-5. PubMed ID: 750114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monocyte function in Hodgkin's disease.
    Holm G; Björkholm M; Johansson B; Mellstedt H; Lindemalm C
    Clin Exp Immunol; 1982 Jan; 47(1):162-8. PubMed ID: 7094420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological capacity of lymphocytes from untreated patients with Hodgkin's disease evaluated in mixed lymphocyte culture.
    Björkholm M; Holm G; Mellstedt H; Pettersson D
    Clin Exp Immunol; 1975 Dec; 22(3):373-7. PubMed ID: 131665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T, B and K cells in autoimmune thyroid disease.
    Calder EA; Irvine WJ; Davidson NM; Wu F
    Clin Exp Immunol; 1976 Jul; 25(1):17-22. PubMed ID: 1086749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subpopulations of human T lymphocytes in patients with Hodgkin's disease before and after treatment.
    Karande AA; Gulwani B; Advani SH; Gangal SG
    Neoplasma; 1982; 29(2):149-59. PubMed ID: 6981068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.